Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D. Hornak T, et al. Among authors: cmunt e. Am J Hematol. 2024 Apr;99(4):763-766. doi: 10.1002/ajh.27229. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38317312
Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry.
Faber E, Mužík J, Koza V, Demečková E, Voglová J, Demitrovičová L, Chudej J, Markuljak I, Cmunt E, Kozák T, Tóthová E, Jarošová M, Dušek L, Indrák K. Faber E, et al. Among authors: cmunt e. Eur J Haematol. 2011 Aug;87(2):157-68. doi: 10.1111/j.1600-0609.2011.01637.x. Eur J Haematol. 2011. PMID: 21535160
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D, Klamova H, Muzik J, Cmunt E, Racil Z, Machova Polakova K, Dvorakova D, Jurcek T, Razga F, Cetkovsky P, Dusek L, Mayer J. Zackova D, et al. Among authors: cmunt e. Leuk Lymphoma. 2013 Oct;54(10):2310-3. doi: 10.3109/10428194.2013.772173. Epub 2013 Feb 28. Leuk Lymphoma. 2013. PMID: 23373966 No abstract available.
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, Steinerová K, Karas M, Faber E, Demečková E, Michalovičová-Sninská Z, Voglová J, Demitrovičová L, Mikušková E, Tóthová E, Chudej J, Markuljak I, Cmunt E, Moravcová J, Dvořáková D, Michalová K, Jarošová M, Sťastná MM, Cetkovský P, Dušek L, Koza V, Trněný M, Indrák K. Klamová H, et al. Among authors: cmunt e. Cancer Med. 2013 Apr;2(2):216-25. doi: 10.1002/cam4.59. Epub 2013 Feb 21. Cancer Med. 2013. PMID: 23634289 Free PMC article.
Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.
Pavlik T, Janousova E, Mayer J, Indrak K, Jarosova M, Klamova H, Zackova D, Voglova J, Faber E, Karas M, Machova Polakova K, Racil Z, Demeckova E, Demitrovicova L, Tothova E, Chudej J, Markuljak I, Cmunt E, Kozak T, Muzik J, Dusek L. Pavlik T, et al. Among authors: cmunt e. Am J Hematol. 2013 Sep;88(9):790-7. doi: 10.1002/ajh.23508. Epub 2013 Jul 23. Am J Hematol. 2013. PMID: 23760739 Free article.
Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
Schwarz J, Ovesná P, Černá O, Kissová J, Maaloufová Soukupová J, Brychtová Y, Doubek M, Červinek L, Cmunt E, Dulíček P, Campr V, Křen L, Penka M; CZEMP-Czech Group for Ph- Myeloproliferative Disorders. Schwarz J, et al. Among authors: cmunt e. Eur J Haematol. 2016 Jan;96(1):98-106. doi: 10.1111/ejh.12554. Epub 2015 Apr 21. Eur J Haematol. 2016. PMID: 25807961
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, Mayer J. Žáčková D, et al. Among authors: cmunt e. Leukemia. 2024 Apr;38(4):893-897. doi: 10.1038/s41375-024-02215-9. Epub 2024 Mar 12. Leukemia. 2024. PMID: 38472478 Free PMC article. No abstract available.
38 results